January 25, 2017
Vectura Group reached $512M Novartis’s drugs, triggers milestone of $5M
Vectura Group has triggered milestone receipt of $5 million from Novartis by reaching $512 million combined net sales of Seebri,…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Novartis
January 25, 2017
Novartis 2016 full year net income down 6%
Novartis delivered a solid performance in 2016, absorbing Gleevec US loss of exclusivity while investing in key launches and the Alcon Division turnaround
January 6, 2017
Novartis and Ionis team on cardiovascular treatments
Novartis and Ionis Pharmaceuticals with its affiliate Akcea Therapeutics have signed an agreement for licensing two novel treatments for reducing cardiovascular risk in patients with high levels of lipoproteins known as Lp(a) and ApoCIII.
January 4, 2017
Gilead reinforces oncology department from Novartis
Gilead Sciences has strengthened its lines with newly appointed Hematology and Oncology Therapeutic Area Head, who came from Novartis.
December 20, 2016
Novartis buys private US-based pharma company, exapnds its ophtalmology pipeline
Novarits is expanding its ophthalmology pipeline as it secured the ownership of a US-based private company focused on treating long-sightedness.
December 20, 2016
Silence Therapeutics settles with Quark Pharmaceuticals
Silence Therapeutics and Quark Pharmaceuticals have settled in the arbitration regarding a milestone payment, as Silence is to receive a…
December 20, 2016
Novartis, Conatus in borad deal to make treatments for liver diseases
Novartis and Conatus Pharmaceuticals have signed a multipurpose deal which will help the two drug makers to make liver-disease treatment,…
December 16, 2016
Novartis’s epilepsy drug gets CHMP’s positive opinion
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for…
December 16, 2016
Novartis buys Ziarco Group
Novartis has entered into a definitive agreement to buy a privately held company Ziarco Group Limited, focused on producing dermatology…
December 12, 2016
Novartis’s Monaleesa study show PFS in breast cancer treatment
Novartis has announced additional analyses from the Phase III MONALEESA-2 study that show LEE011 (ribociclib) plus letrozole significantly prolonged progression-free…